The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

The Pharma Data

JANUARY 24, 2021

25, 2021 /PRNewswire/ — Therapeutic Solutions International, Inc., (OTC Technologies developed by Therapeutic Solutions International allow for the manufacture of unique dendritic cells from cord blood stem cells, which can be used in a universal donor manner. . OCEANSIDE, Calif., Source link.

International 40

International Laboratories Therapies Treatment 40

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.

Disease 52

Disease FDA Treatment Clinical Trials 52

The Pharma Data

JANUARY 25, 2021

“The establishment of an Advisory Board focusing on Alzheimer’s disease, and the recruitment of such an impressive group of scientific and clinical leaders in this field is an extremely important step forward for the Company,” stated Paul Brennan, NervGen’s President & CEO. Dr.

Disease 40

Disease Clinical Development Molecular Biology Treatment 40

Drug Target Review

APRIL 9, 2024

How has nucleolar stress (NS) been linked to age-related diseases, and what approach did researchers use to investigate its toxicity? The nucleolus (and nucleolar stress) had been previously linked to aging and age-related diseases such as cancer or degeneration.

RNA 64

RNA Cell Biology Clinical Development DNA 64

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

LifeSciVC

JANUARY 16, 2024

The expectation that Pharma will continue buy-ups here is helping to fuel conviction for another strong year ahead for M&A, especially for those acquirers who will rely on inorganic acquisition to build in areas under-represented by internal R&D (e.g., Additional trials (e.g.,

Small Molecule 138

Small Molecule Trials Therapies Disease 138

Drug Target Review

DECEMBER 13, 2024

These types differ in their etiology, natural history, and present distinct challenges in disease management. 3,4 However, inter- and intra-tumoural heterogeneity is widespread in lung cancer, leading to multiple mechanisms through which these tumours can and do develop resistance to treatment. percent of total cancer fatalities.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

LifeSciVC

APRIL 24, 2024

Target validation : Do we believe the target(s) plays a central role in disease biology and that modulation will modify disease? I will note that “de-risked” is never fully risk-free in therapeutics investing, as even precedented mechanisms hit stumbling blocks in preclinical or clinical development.

Production 114

Production Small Molecule Regulations Trials 114

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

Drug Target Review

SEPTEMBER 26, 2023

Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. 1-4 This approach saves time, money, and resources, and ultimately leads to safer medicines going forward to the clinic. International Union of Pharmacology. Pharmacol Rev.

Drugs 111

Drugs FDA Disease Animal Testing 111

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Vial

MARCH 25, 2024

Worldwide Clinical Trials is a mid-size, full-service global contract research organization (CRO) that works with biotech and pharma to advance new medications. With an international presence in nearly 60 countries, Worldwide is supported by over 3,400 team members.

Clinical Trials 52

Clinical Trials Trials Clinical Development Clinical Research 52

NIH Director's Blog: Drug Development

JUNE 14, 2016

People with type 2 diabetes are at increased risk for heart attacks, stroke, and other forms of cardiovascular disease, and at an earlier age than other people. In fact, the evidence suggests that such drugs might even offer some protection against heart disease. Food and Drug Administration. December 2008. [2] Sci Transl Med.

Drugs 52

Drugs Disease Drug Development Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. This patient population is at significant risk of developing cardiovascular complications, which are frequently fatal, during their illness.

Hospitals 52

Hospitals Trials International Clinical Trials 52

Drug Target Review

DECEMBER 28, 2023

Patients with high numbers of clonal neoantigens show improved disease-free survival. Sergio co-led the development of a first-in-class Treg-depleting anti-human CD25 antibody with TUSK Therapeutics, which was acquired by Roche in 2018 and is currently under clinical evaluation.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

OCTOBER 26, 2020

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. During the conference call, the Company will review its financial results and provide a corporate update. The conference ID number for the call is 8557525.

Clinical Trials 52

Clinical Trials Clinical Development Trials Engineering 52

The Pharma Data

JANUARY 4, 2021

BOSTON–( BUSINESS WIRE )– PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D.,

Disease 52

Disease International Clinical Trials Production 52

The Pharma Data

JANUARY 6, 2021

He continues: “With the green light granted by the FDA to continue our clinical research, we are one step closer to offering psoriasis patients a novel, improved oral treatment option and thereby enhancing their quality of life. UNION is headquartered in Hellerup ( Denmark ) and is managed by an experienced international team.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

JANUARY 14, 2021

Awakn’s Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical trial designed to investigate the safety and efficacy of MDMA as a pharmacological treatment for Alcohol Use Disorder. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide.

Science 52

Science Treatment Clinical Trials Clinical Development 52

The Pharma Data

OCTOBER 14, 2020

International Dial-in Number: (210) 874-7715. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. WALTHAM, Mass., Time : 4:30 p.m.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . This may suggest a potential disease-modifying effect of lecanemab.

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

Drug Target Review

JULY 26, 2024

However, we see applications across the entire drug development life cycle, from target discovery and biomarker development to clinical development programmes and finding patients for clinical trials based upon both genotypic and phenotypic criteria. The second category would be our internal team of researchers.

Clinical Trials 72

Clinical Trials Science Trials International 72

The Pharma Data

JANUARY 27, 2021

Batoclimab (HBM9161) , a fully human anti-FcRn mAb, blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases. “In China, large numbers of patients suffer IgG-mediated autoimmune diseases including MG, ITP, NMOSD, among others.

Therapies 40

Therapies Treatment International Licensing 40

Drug Target Review

OCTOBER 10, 2024

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? This can lead to low cell yields, poor product quality, and process variability.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

The Pharma Data

NOVEMBER 30, 2020

Dr. Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13713850.

Science 40

Science Clinical Trials Disease Clinical Development 40

Vial

APRIL 10, 2024

Moreover, IQVIA offers strategic partnership opportunities, multi-year contracts, and quick access to project managers and clinical research associates1,3. Moreover, IQVIA offers strategic partnership opportunities, multi-year contracts, and quick access to project managers and clinical research associates1,3.

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

The Pharma Data

DECEMBER 13, 2020

which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. –( BUSINESS WIRE )– EdiGene, Inc. as Head of the US Subsidiary, and Kehua Fan, M.D.,

Medical Schools 40

Medical Schools Clinical Development Therapies RNA 40

The Pharma Data

OCTOBER 15, 2020

ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide. SINGAPORE, Oct. The company expects to share further details in early 2021. M edia and IR contacts.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

The Pharma Data

JANUARY 27, 2021

.–( BUSINESS WIRE )– PlateletBio , a pioneering biotechnology company developing next-generation allogeneic cell therapies for treatment of human diseases, has named Steven M. Altschuler, M.D., as Chairman of its Board of Directors. “As President and CEO of PlateletBio. The company, based in Watertown, Mass.,

Therapies 40

Therapies Engineering Clinical Development Disease 40

The Pharma Data

MARCH 1, 2022

The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer’s disease and major depressive disorder. senior vice president, R&D, chief scientific officer, AbbVie.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

SEPTEMBER 6, 2021

Given the high unmet medical need, we are very encouraged with the positive outcome of eliapixant in the chronic cough indication regarding efficacy and safety,” said Christian Rommel, Member of the Executive Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development. About the Phase IIb Study.

Trials 52

Trials Clinical Trials Treatment International 52

The Pharma Data

JANUARY 31, 2021

Joint drug discovery program to focus on a single ion channel that is a well-validated target for neurological diseases. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs Disease 52

The Pharma Data

NOVEMBER 10, 2020

The NCT03763149 study is a phase 1a clinical study evaluating the tolerability, safety, and PK/PD properties of IBI188 (letaplimab) as monotherapy for advanced malignancies that failed in standard treatments. . The study preset 7 dose groups ranging from 0.1mg/kg to 30mg/kg. About Innovent.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

DECEMBER 8, 2020

Some of the funds will be used for the development of therapeutics for oncology and other serious diseases through its proprietary ImmunoTAC technology platform. The ImmunoTAC platform pairs proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

JANUARY 3, 2021

InspirMed is a newly established subsidiary of TLC specializing in the development of inhalable liposome formulation programs, such as TLC19 for the treatment of Coronavirus disease 2019 (COVID-19) as well as other programs for severe acute and chronic pulmonary diseases. Cautionary Note on Forward-Looking Statements.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Disease 52